Skip to main content

Table 4 Comparison of peripheral blood lymphocyte subpopulations in drug-resistant epilepsy, drug-responsive epilepsy, drug-naïve epilepsy, and healthy controls

From: The correlation of GluR3B antibody with T lymphocyte subsets and inflammatory factors and their role in the progression of epilepsy

 

units

Drug-resistant patients (n = 64)

Drug-responsive patients (n = 41)

Drug-naïve

patients (n = 66)

Healthy control

(n = 40)

P

CD3+CD19−

%PBMCs

70.7 ± 6.6

72.2 ± 8.0

70.0 ± 8.6

69.4 ± 5.7

0.30

CD3−CD19+

%PBMCs

13.8 ± 4.5

12.0 ± 4.8

14.1 ± 6.4

13.1 ± 2.8

0.15

CD3−CD16+56+

%PBMCs

14.1 ± 5.2

13.9 ± 7.3

13.7 ± 7.3

12.3 ± 3.7

0.35

CD3+CD4+

%PBMCs

39.5 ± 5.9

40.1 ± 7.3

40.6 ± 7.9

37.7 ± 3.7

0.11

CD3+CD8+

%PBMCs

25.2 ± 6.5

26.1 ± 7.8

24.5 ± 9.3

23.9 ± 4.5

0.37

CD4+/CD8+

 

1.7 ± 0.7

1.7 ± 0.6

1.9 ± 1.0

1.8 ± 0.5

0.61

CD3+CD4−CD8−

%PBMCs

6.9 ± 2.9

6.9 ± 4.3

6.1 ± 3.8

6.0 ± 3.2

0.15

CD4+CD25high

%PBMCs

2.3 ± 1.4

2.7 ± 1.4

2.7 ± 1.3

2.5 ± 1.2

0.28